SOX7

Across TCGA pan-cancer cohorts, SOX7 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SOX7 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher SOX7 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SOX7 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

BLCA, SKCM, and STAD are the cancer types where SOX7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.196	0.592	.042	6	view →
SKCM	DFS	Median	All	0.479	0.200	.022	4	view →
STAD	OS	Median	II,III,IV	0.211	0.572	.040	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

SOX7–BLCA (OS)

Open the BLCA breakdown →